Merck (MRK) stock tumbles as slowing China sales for its HPV prevention drug, Gardisil, weigh on the company's outlook. PepsiCo (PEP) shares are under pressure following a cautious forecast due to ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. It is the first time that Merck has ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target to $119.00. Discover outperforming stocks and invest ...

Merck is speeding up plans to launch a new version of its top-selling cancer drug Keytruda, with less than three years to go before the patents protecting the original version expire. Keytruda ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of the year, accelerating the company’s efforts to protect its top ...